GlassScriptPhysician profile
Brian Shanklin Weaver
NPI 1104988328
$5,690.76
in general payments reported to CMS, 2019-2025
27 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,940 · 2020: $402 · 2021: $601 · 2022: $649 · 2023: $301 · 2024: $273 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,378.79 | 2019-2025 | Proclaim, Octrode, Eterna |
| Si-Bone, INC. | $427.36 | 2019-2022 | |
| Assertio Therapeutics, INC. | $313.21 | 2019-2020 | |
| Almatica Pharma LLC | $248.16 | 2021-2023 | Gralise |
| Globus Medical, INC. | $210.42 | 2023-2025 | Excelsiusgps Robotic Navigation System, Xlif, Senza |
| Arbor Pharmaceuticals, INC. | $137.20 | 2020-2022 | |
| Intrinsic Therapeutics | $122.44 | 2025 | Barricaid Acd (Annular Closure Device) |
| Azurity Pharmaceuticals, INC. | $114.69 | 2023-2024 | Horizant, Horizant |
| Nevro Corp. | $85.80 | 2019-2023 | Senza |
| Bioventus LLC | $73.32 | 2020-2022 | |
| Pfizer INC. | $69.01 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $66.91 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $66.01 | 2019 | |
| Electronic Waveform Lab, INC. | $49.92 | 2019-2021 | |
| Boston Scientific Corporation | $44.88 | 2021-2025 | Wavewriter Alpha Prime 16 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $37.02 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $35.97 | 2019 | |
| Lundbeck LLC | $29.57 | 2022 | |
| Pacira Therapeutics, INC. | $27.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.65 | 2020 | |
| Hikma Pharmaceuticals USA | $22.61 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.29 | 2021 | |
| Fidia Pharma USA INC. | $19.72 | 2025 | Hymovis |
| Baudax Bio INC. | $16.81 | 2020 | |
| Kaleo, INC. | $15.37 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.